Abstract
11[beta]-HSD type 1 inhibitor ameliorates metabolic disorders associated with hypercortisolemia: A clinical trial to assess its safety and efficacy in Japanese patients with refractory Cushing's syndrome and subclinical Cushing's syndrome
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have